LLY,ENDP -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • MarketWatch39 minutes ago

    Pfizer, Eli Lilly non-opioid pain drug nears finish line

    A new non-opioid drug for osteoarthritis pain being developed by Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY) had positive early results in a phase 3 clinical trial, the companies announced on Wednesday. Patients who received two doses of the drug had a statistically significant improvement in pain, physical function and their own assessment of their osteoarthritis, relative to patients on the placebo. More information about progressive osteoarthritis seen in patients is still needed, though, said EvercoreISI analyst Umer Raffat, and the companies in particular "likely [need] longer follow up before being more definitive" about tanezumab's safety.

  • Reuters2 hours ago

    Pfizer-Lilly pain drug meets late-stage trial goals

    The treatment, tanezumab, belongs to an investigational category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and is also being evaluated to treat chronic lower back and cancer pain. U.S. regulators in 2015 lifted a hold on trials of medicines targeting the protein due to concerns they could worsen osteoarthritis in a small percentage of patients. Pfizer's shares were marginally up at $37.79 in premarket trade.

  • Reuters2 hours ago

    Pfizer-Lilly pain drug meets late-stage trial goals

    An experimental osteoarthritis drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of lowering pain in a late stage trial, the companies said on Wednesday, potentially offering a safer alternative to opioids. The treatment, tanezumab, belongs to an investigational category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and is also being evaluated to treat chronic lower back and cancer pain. U.S. regulators in 2015 lifted a hold on trials of medicines targeting the protein due to concerns they could worsen osteoarthritis in a small percentage of patients.

  • See what the IHS Markit Score report has to say about Endo International PLC.
    Markit3 hours ago

    See what the IHS Markit Score report has to say about Endo International PLC.

    Endo International PLC NASDAQ/NGS:ENDP

  • Analyst Recommendations for Valeant Pharmaceuticals in July
    Market Realist2 days ago

    Analyst Recommendations for Valeant Pharmaceuticals in July

    In July, the FDA accepted Bausch + Lomb’s NDA (New Drug Application) for sub-micron loteprednol etabonate for the treatment of patients who have undergone ocular surgery and are showing symptoms of post-operative inflammation and pain.

  • J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay
    Zacks2 days ago

    J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay

    The FDA defers decision regarding label expansion application to include cardiovascular indication on the label of J&J's (JNJ) diabetes drug Invokana.

  • The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon
    Zacks2 days ago

    The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon

    The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon

  • 3 Dividend Stocks That Should Pay You the Rest of Your Life
    Motley Fool3 days ago

    3 Dividend Stocks That Should Pay You the Rest of Your Life

    These buy-and-hold dividend stocks can be counted on for income.

  • Here are Q2's 10 biggest VC-backed exits from the Bay Area
    American City Business Journals5 days ago

    Here are Q2's 10 biggest VC-backed exits from the Bay Area

    Here is a look at the 10 biggest venture-backed IPOs and acquisitions from the first half of what has been a very active year for such exits.

  • Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom
    Zacks5 days ago

    Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom

    Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom

  • Better Buy: Acadia Pharmaceuticals vs. Eli Lilly
    Motley Fool5 days ago

    Better Buy: Acadia Pharmaceuticals vs. Eli Lilly

    Which stock wins in a battle between a small, beaten-down biotech and an established major drugmaker?

  • What Endo International’s Valuation Trend Indicates
    Market Realist6 days ago

    What Endo International’s Valuation Trend Indicates

    Endo International’s (ENDP) U.S. Branded – Sterile Injectables segment includes branded sterile injectable products such as Vasostrict, Adrenalin, and Aplisol, and generic sterile injectable products such as ephedrine sulphate injection and neostigmine methylsulfate injection. Revenues from this segment increased from $172.17 million in Q1 2017 to $215.85 million in Q1 2018.

  • Endo’s Generic and International Segments Declined in Q1 2018
    Market Realist6 days ago

    Endo’s Generic and International Segments Declined in Q1 2018

    Under Endo International’s (ENDP) established products, Percocet sales increased from $30.94 million in Q1 2017 to $31.97 million in Q1 2018. The increase was attributable to higher prices, partially offset by a decline in volume. Voltaren gel sales, on the other hand, decreased from $14.27 million in Q1 2017 to $11.32 million in Q1 2018 due to lower prices resulting from generic competition. Sales from other established products also decreased, from $64.48 million in Q1 2017 to $45.03 million in Q1 2018.

  • Analyzing Endo International’s Financial Performance
    Market Realist6 days ago

    Analyzing Endo International’s Financial Performance

    Endo International (ENDP) generated revenues of $700.5 million in the first quarter compared to $1.04 billion in Q1 2017. Endo International incurred a cost of revenues of $403.59 million in the first quarter compared to $668.96 million in Q1 2017. Its gross profit was $296.93 million in the first quarter compared to $368.64 million in Q1 2017.

  • Endo International’s Specialty and Established Products in Q1
    Market Realist6 days ago

    Endo International’s Specialty and Established Products in Q1

    Endo International’s (ENDP) net interest expense increased from $111.9 million in Q1 2017 to $123.9 million in Q1 2018. While the company received an income tax benefit of $11.9 million in Q1 2017, it had an income tax expense of $15.49 million in Q1 2018. That led to an increase in its net loss from $173.83 million in Q1 2017 to $505.48 million in Q1 2018. That translated to a net loss per share of $2.26 in Q1 2018 compared to a net loss per share of $0.78 in Q1 2017.

  • What Analysts Think of Endo International
    Market Realist6 days ago

    What Analysts Think of Endo International

    Of the 19 analysts covering Endo International (ENDP) stock in July, four of them have given the stock a “buy” or higher rating, 14 have given it a “hold,” and one has given it a “sell.” The mean rating for the stock is 2.74 with a target price of $8.53. Sixteen of the 20 analysts covering Abbott Laboratories (ABT) in July have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $69.

  • The Sad Truth: This Biotech Investing Strategy Almost Always Works
    Motley Fool7 days ago

    The Sad Truth: This Biotech Investing Strategy Almost Always Works

    We want researchers to cure disease. But the honest truth is that you could potentially make a fortune by betting against drugmakers in this indication.

  • Barrons.com7 days ago

    [$$] Big Stock Buys in IBM, Lilly by Norway's Biggest Bank

    The last time we checked in with DnB, it had sold more than half of its investment in Intel. Norway’s largest and oldest private financial institution (established 1822) slashed its holdings in Intel (INTC) to 1.7 million shares from 3.8 million shares in the first quarter. DnB seemed to have a rethink in the second quarter, however, buying 537,300 more shares of the chip giant and raising its investment to 2.3 million shares as of June 30.

  • InvestorPlace8 days ago

    Trump Tweets Threat to Pfizer but Investors Shrug it Off

    Pfizer (NYSE:PFE) was the target of a Presidential tweet tantrum Monday over its second price hike of the year but investors shrugged it off.

  • InvestorPlace8 days ago

    Biogen Is the Right Alzheimer’s Stock … At the Wrong Time

    On Friday, Biogen (NASDAQ:BIIB) shares soared on news that one of its Alzheimer’s drug trials was showing tremendous promise. Specifically, BIIB stock jumped nearly 20% after an update on BAN-2401, a phase 2 drug that showed a statistically significant slowdown in the memory loss associated with Alzheimer’s. BAN-2401, an antibody that takes aim at the amyloid plaque in the brain that’s thought to be a key cause of Alzheimer’s, was cast into a questionable light late last year.

  • A Look at Incyte’s Product Portfolio in July
    Market Realist8 days ago

    A Look at Incyte’s Product Portfolio in July

    Incyte’s (INCY) product portfolio includes targeted therapies and immuno-therapies for oncology and non-oncology diseases. Incyte’s product portfolio includes 17 molecular targets and 19 clinical candidates. The chart below shows its revenues from collaborations since the first quarter of 2017.

  • Incyte’s Quarterly Revenue Stream
    Market Realist8 days ago

    Incyte’s Quarterly Revenue Stream

    Incyte Corporation (INCY) reported revenues of $382.3 million during the first quarter, a marginal decline in YoY (year-over-year) revenues compared to $384.1 million during the first quarter of 2017. These revenues include the product revenues from sales of Jakafi and Iclusig, royalty revenues from Jakavi and Olumiant, and milestone and contract revenues. The chart below compares the revenues for Incyte since the first quarter of 2017.

  • Better Buy: Eli Lilly and Company vs. AbbVie
    Motley Fool9 days ago

    Better Buy: Eli Lilly and Company vs. AbbVie

    Both of these pharmaceutical giants face competitive threats, but both have strong pipelines.

  • Zoetis and Abaxis Announce Antitrust Clearance for Merger
    Market Realist9 days ago

    Zoetis and Abaxis Announce Antitrust Clearance for Merger

    On July 6, Zoetis (ZTS) and Abaxis (ABAX) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

  • See what the IHS Markit Score report has to say about Endo International PLC.
    Markit11 days ago

    See what the IHS Markit Score report has to say about Endo International PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ENDP totaled $3.08 billion.